IL33 and Alzheimer disease: Exogenous IL-33 administration significantly polarized microglia toward an anti-inflammatory phenotype, reduced pro-inflammatory gene expression, and enhanced the phagocytic activity of microglia, thereby improving Aβ pathology in AD mice by promoting the recruitment of microglia and decreasing amyloid plaque deposition67,68.